Drug-coated balloon versus drug-eluting stent for femoropopliteal total occlusions: intraluminal versus subintimal approaches

Abstract

Because there is a lack of comparative studies assessing drug-coated balloon (DCB) and drug-eluting stent (DES) outcomes with respect to intraluminal (IL) and subintimal (SI) approaches in femoropopliteal (FP) total occlusive lesions, we compared the outcomes between DCB (including bailout stenting) and DES treatments for this lesion. A total of 487 limbs (434 patients) were divided into the IL (n = 344, DCB: n = 268, DES: n = 76) and SI (n = 143, DCB: n = 83, DES: n = 60) approach groups. The primary outcome was a major adverse limb event (MALE), defined as above-ankle amputation or repeat revascularization of the index limb. Secondary outcomes included clinically driven target lesion revascularization (TLR), loss of clinical patency, and all-cause death. After adjustment, in each IL and SI approach, the 2-year rates of MALE (p = 0.180 and p = 0.236, respectively), TLR, loss of clinical patency, and all-cause death were similar between the DCB and DES groups. In the DCB and DES groups, both primary and secondary outcomes were similar between the IL and SI approaches. DCB and DES strategies for patients presenting with FP total occlusive lesions demonstrated similar outcomes regardless of the IL or SI approach.Clinical Trial Registration: NCT02748226.

Keywords: Chronic total occlusion; Drug-coated balloon; Drug-eluting stent; Femoropopliteal artery disease.

Fig. 1

Flowchart. EVT endovascular therapy,K-VIS ELLA The Korean Vascular Intervention Society Endovascular therapy in Lower Limb Artery Diseases, FPA Femoropopliteal artery, POBA plain old balloon angioplasty, BMS bare-metal stent, DCB drug-coated balloon(including bailout stent group) group, DES drug-eluting stent group.

Fig. 2

Kaplan–Meier curve analysis for MALE (A), TLR (B), loss of clinical patency (C), and all-cause death (D).